Quantum BioPharma is trading at $2.98, up 5.67%, after its October 12 after-hours rise, for which no clear company-specific catalyst was identified. - The Thermo Fisher agreement for the Lucid-MS Phase 2 trial was announced October 6, making it prior news rather than a confirmed new catalyst. - The broader market was mixed and largely flat on October 12, offering no clear market-wide explanation for the move.